BioSpace News Archive

Pfizer’s oral antiviral treatment for COVID-19 is making its way through regulatory hurdles. The company is working with global manufacturers to ensure a steady supply of the medication.

ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies, announced the completion of a $250 million Series B financing led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital, and Westlake Village BioPartners.

AOBiome’s 547 subject Phase 2b trial for Treatment of Pruritus (Itch) Associated with Atopic Dermatitis (Eczema) successfully completes its recruitment goal

NorthSea Therapeutics B.V., a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, announces the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience™ 2021 of the American Association for the Study of Liver Diseases, which was held online from November 12-15.

Biovica, active in cancer diagnostics, announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics.

Canadian pharmacogenetic testing provider, Inagene Diagnostics Inc., has partnered with The Newly Institute, an advanced network of medically assisted psychotherapy clinics in Canada, specializing in outpatient programs for mental health, addiction and chronic pain.

Patient dosing has begun in a Phase 1b/2a clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1 in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters location in Myrtle Beach, South Carolina.